Since type-1 immune effector cells, including Th1 cells and cytotoxic CD8+ T cells, are the most effective anti-tumor immune cells, induction of the three CXCR3 ligands appears to be a valuable goal, possibly in combination with checkpoint blockage inhibitors (CBIs) that release the molecular brakes on tumor infiltrating lymphocytes (TILs). The gene discussed is CXCR3; the disease is neoplasm.